Evidence map›Paper›PMID 41977432›Full record

ArticleInternational journal of molecular sciences2026

Preclinical Evaluation of Triptophenolide-Induced Apoptosis in Hepatoblastoma (HepG2) and Hepatocellular Carcinoma (HuH7) Cell Lines.

Zufa Sabeel, Ruolan Chen, Yan Liu, Xiaoyang Chen, Wenjing Zhang, Shangyang Pan, Lu Ying, Changyuan Yu, Zhao Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zufa SabeelCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Ruolan ChenCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Yan LiuCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Xiaoyang ChenCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Wenjing ZhangCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Shangyang PanCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Lu YingCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Changyuan YuCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.
Zhao YangCollege of Life Science and Technology, State Key Laboratory of Green Biomanufacturing, Innovation Center of Molecular Diagnostics, Beijing University of Chemical Technology, Beijing 100029, China.ORCID 0000-0003-2856-7167

Funding

Joint Project of Biomedical Translational Engineering Research Center of Beijing University of Chemical Technology-China-Japan Friendship Hospital XK2023-21Major Research Plan of the National Natural Science Foundation of China 92359202National Key Research and Development Program 2024YFC3405500Open Competition to Select the Best Candidates" Key Technology Program for Nucleic Acid Drugs of NCTIB NCTIB2022HS01016
6 · The paper itself

Abstract

Liver cancer is one of the most prevalent and lethal cancers worldwide, characterized by poor prognosis and limited treatment options. Triptophenolide (TRI), a diterpenoid compound, has shown anti-proliferative activity in breast and pancreatic cancers, but its role in liver cancer remains largely unexplored. In this study, TRI significantly inhibited the proliferation of HepG2 (hepatoblastoma) and HuH7 (hepatocellular carcinoma) cells in a dose-dependent manner, with IC

Indexed as

Antineoplastic AgentsApoptosisCarcinoma, HepatocellularDiterpenesHepatoblastomaLiver NeoplasmsAnimalsCell Line, TumorCell ProliferationHep G2 CellsHumansMiceMice, NudeXenograft Model Antitumor AssaysAntineoplastic AgentsDiterpenesantitumor effectapoptosisliver cancerproliferationTriptophenolidexenograft model

Identifiers

PMID41977432
PMCPMC13074054

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.